On May 7, 2024 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519), National Cancer Center Hospital (hereafter, NCCH), Osaka Medical and Pharmaceutical University (hereafter, OMPU) and MICIN reported introduction of a new decentralized clinical trial (DCT)* structure and the start of DCT in a Chugai-sponsored phase I clinical trial for patients with advanced solid tumors (Press release, Chugai, MAY 8, 2024, View Source;category= [SID1234642809]). NCCH and OMPU will collaborate using telemedicine as the primary institution and the satellite institution,** respectively, and some tests and assessments that were conventionally performed at institutions will be performed at the satellite institution.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This is the first study in Japan to utilize a satellite institution for a company-sponsored phase I clinical trial in oncology. Since the number of institutions is very limited in phase I clinical trials, it is expected to improve access to clinical trials of new drug candidates for patients living far from institutions. We will evaluate this new DCT structure, with the aim of building an implementation structure that provides access to clinical trials for many patients regardless of where they live.
[Background and details]
Since clinical trials of new drug candidates are conducted at a limited number of medical institutions, some patients living far from the institution give up their participation in the clinical trial due to the time and financial burden associated with in-person visits. Establishing an environment that improves the patients’ access to clinical trials is a common challenge in clinical development, including pharmaceutical companies and academias.1 A retrospective study conducted at NCCH also showed that the participation rate in clinical trials tended to decrease for patients with travel time of 120 minutes or more.2 In addition, in phase I clinical trials evaluating drug safety for cancer patients, it is necessary to closely monitor patients’ condition while ensuring the patients’ safety. Therefore, there are few medical institutions where phase I clinical trials can be conducted.
DCTs, which are not dependent on in-person visits, have been attracted attention as a new approach in recent years. In Japan, some guidelines have been issued, and DCT is gradually being introduced into clinical trials, but the use in the oncology area is still limited.
This is a Chugai-sponsored phase I clinical trial for patients with advanced solid tumors, conducted with NCCH as a primary institution and OMPU as a satellite institution. Since the travel time from OMPU to NCCH exceeds 120 minutes, DCT is expected to reduce patients’ burdens. Patients will be able to visit the satellite institution instead of the primary institution to receive some tests and assessments for this clinical trial via telemedicine. The DCT platform MiROHA, provided by MICIN, will also be utilized for telemedicine visits and for obtaining remote re-consent using eConsent.
Improving access for patients is a common challenge in the pharmaceutical industry because clinical trials of new drug candidates are conducted at a limited number of medical institutions. The utilization of satellite institutions is expected to reduce the burden on patients and improve access to clinical trials. Chugai’s most prioritized value is patient-centricity. We will develop new drugs together with patients as partners, with the aim of realizing advanced and sustainable patientcentric healthcare.
Dr. Osamu Okuda, President and CEO, Chugai Pharmaceutical Co., Ltd.
To patients living in remote areas, access to clinical trials is drastically reduced, especially true for rare cancers and those of rare fractions, which trials are concentrated in hospitals in urban centers. By removing the need for patients to commute long hours, DCTs can address this issue. With new means, our team will reinvigorate drug development in Japan, delivering treatments expeditiously to patients nationwide, which is our mission.
Dr. Yasuyuki Seto, Director of National Cancer Center Hospital
In the phase I clinical trial for solid tumors, our institution will play a role as a satellite institution, contributing to the implementation of "no one left behind in cancer care" practices. In the face of disparities in access to clinical trials and information, particularly in rural areas, we have established a decentralized clinical trial system aimed at reducing the burden on patients while addressing these disparities. We have experience in many phase I trials of new anti-cancer drugs, and we are committed to the success of this challenging trial and will endeavor to ensure the realization of cancer patients’ "Well Being" even in rural regions.
Dr. Takahiro Katsumata, Osaka Medical and Pharmaceutical University Hospital
It is hoped that this trial initiative, which utilizes satellite medical institutions, will reduce the burden on patients and expand their options for participating in clinical trials.
As a leading DCT company, we are committed to contributing to a new way of conducting clinical trials through this new attempt.
Dr. Seigo Hara, MICIN, Inc., Representative CEO